# Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

> **NCT03803475** · PHASE3 · COMPLETED · sponsor: **Thomas Hope** · enrollment: 485 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ga-68 labeled PSMA-11
- **DEVICE:** Positron emission tomography-computed tomography (PET/CT)
- **DEVICE:** Positron emission tomography-magnetic resonance imaging (PET/MRI)

## Key facts

- **NCT ID:** NCT03803475
- **Lead sponsor:** Thomas Hope
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2020-08-25
- **Final completion:** 2020-08-25
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803475, "Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03803475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*